Express Scripts' Friendly Data Play
Executive Summary
PBMs have historically positioned themselves as drug-industry antagonists, pushing generic substitution and aggressively driving prices lower. But now one independent PBM is arguing that far from being in the enemy camp, branded pharmaceuticals, even high cost ones, can actually contribute to reducing overall medical costs by lowering spending in other areas. And they're developing the data to prove it.
You may also be interested in...
Cosmetic Talc Stakeholders Should Be Watching US EPA Asbestos Developments In 2021
In December, a California federal court ordered the US Environmental Protection Agency to amend its TSCA Chemical Data Reporting rule to address asbestos information-gathering “loopholes,” including a current exemption for asbestos that occurs as an impurity in raw materials such as cosmetic talc.
QUOTED. 28 January 2021. Andrea Riposat.
L'Aquila, Italy-based Dante Laboratories company announced a £30m investment in global surveillance of new variants of the SARS-CoV-2 virus. CEO Andrea Riposat discussed the purchase.
Pharma Companies May Be Asked To Help Competitors Manufacture COVID-19 Vaccines
‘Everything is on the table,’ including invoking the Defense Production Act, White House COVID Coordinator Zients notes. Results of J&J’s Phase III vaccine trial expected ‘within next few days to a week.’
Need a specific report? 1000+ reports available
Buy Reports